<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00077103</url>
  </required_header>
  <id_info>
    <org_study_id>CWRU3302</org_study_id>
    <secondary_id>P30CA043703</secondary_id>
    <secondary_id>CASE-CWRU-3302</secondary_id>
    <secondary_id>CWRU-040337</secondary_id>
    <secondary_id>OXIGENE-CWRU-3302</secondary_id>
    <nct_id>NCT00077103</nct_id>
  </id_info>
  <brief_title>Induction Chemotherapy Using Doxorubicin and Cisplatin Followed by Combretastatin A4 Phosphate and Radiation Therapy in Treating Patients With Newly Diagnosed Regionally Advanced Anaplastic Thyroid Cancer</brief_title>
  <official_title>Phase II Trial of Combined Modality Combretastatin A-4 Phosphate (CA4P)-Based Therapy for Patients With Newly Diagnosed Anaplastic Thyroid Cancer [Induction Chemotherapy With Doxorubicin/Cisplatin; Combined Modality Therapy With CA4P and Radiation; Followed by 2 Cycles of CA4P Consolidation]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as doxorubicin and cisplatin, work in different&#xD;
      ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses&#xD;
      high-energy x-rays to damage tumor cells. Combretastatin A4 phosphate may stop the growth of&#xD;
      cancer by stopping blood flow to the tumor. Combining doxorubicin and cisplatin with&#xD;
      radiation therapy and combretastatin A4 phosphate may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving induction chemotherapy using&#xD;
      doxorubicin and cisplatin together with radiation therapy and combretastatin A4 phosphate&#xD;
      works in treating patients with newly diagnosed regionally advanced anaplastic thyroid&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the objective response rate in patients with newly diagnosed regionally&#xD;
           advanced anaplastic thyroid cancer treated with induction chemotherapy comprising&#xD;
           doxorubicin and cisplatin followed by combretastatin A4 phosphate (CA4P) and&#xD;
           radiotherapy.&#xD;
&#xD;
        -  Determine whether this regimen alters the natural history of anaplastic thyroid cancer&#xD;
           by virtue of doubling the median survival of these patients from 10 to 20 months.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine a tolerable dose of CA4P when administered with radiotherapy in these&#xD;
           patients. (Phase I portion of the study closed as of 5/6/04; patients now receive a&#xD;
           fixed dose of CA4P)&#xD;
&#xD;
        -  Determine the safety profile of this regimen in these patients.&#xD;
&#xD;
        -  Determine clinical predictors of response (e.g., pretreatment tumor microvessel density&#xD;
           and immature vessel staining, changes in sICAM-1 levels and tumor blood flow, and&#xD;
           pharmacokinetic parameters) in patients treated with this regimen.&#xD;
&#xD;
        -  Correlate the diminution in blood flow with tumor pain and response in patients treated&#xD;
           with this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study of combretastatin A4 phosphate (CA4P). (Phase I portion&#xD;
      of the study closed as of 5/6/04; patients now receive a fixed dose of CA4P)&#xD;
&#xD;
        -  Induction phase: Patients receive doxorubicin IV over 5-10 minutes and cisplatin IV over&#xD;
           30-60 minutes on day 1. Patients also receive filgrastim (G-CSF) subcutaneously (SC) on&#xD;
           days 3-21 or pegfilgrastim SC on day 2.&#xD;
&#xD;
        -  Combined modality phase: Beginning on day 22, patients undergo radiotherapy twice daily,&#xD;
           5 days a week, for 3-4 weeks. Patients also receive CA4P IV over 10 minutes weekly on&#xD;
           the fifth day of radiotherapy.&#xD;
&#xD;
      Cohorts of 6 patients receive 1 of 2 escalating doses of CA4P to determine a tolerable dose.&#xD;
      The tolerable dose is defined as the dose at which less than 2 of 6 patients experience&#xD;
      dose-limiting toxicity. (Phase I portion of the study closed as of 5/6/04; patients now&#xD;
      receive a fixed dose of CA4P)&#xD;
&#xD;
        -  Consolidation phase: Beginning 4-6 weeks after the completion of the combined modality&#xD;
           phase, patients receive CA4P IV over 10 minutes on days 1, 8, and 15. Treatment repeats&#xD;
           every 28 days for 2 courses.&#xD;
&#xD;
      Treatment in all phases continues in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      Patients are followed every 2 months for 1 year and then every 3 months for 2 years from&#xD;
      study entry.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 33 patients will be accrued for this study within 18 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    slow accrual&#xD;
  </why_stopped>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median survival</measure>
    <time_frame>at months 2, 4, 6, 8, 10, 12, 15, 18, 21, 24, 27, 30, 33, and 36</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective disease response</measure>
    <time_frame>at the end of induction, combined modality therapy, and consolidation therapy, at 2 months after completion of consolidation therapy, at 2 month intervals during year 1, and then 3 month intervals during years 2 and 3</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">4</enrollment>
  <condition>Head and Neck Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>filgrastim (G-CSF) subcutaneously (SC) on days 3-21 or pegfilgrastim SC on day 2.</description>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pegfilgrastim</intervention_name>
    <description>filgrastim (G-CSF) subcutaneously (SC) on days 3-21 or pegfilgrastim SC on day 2.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>cisplatin IV over 30-60 minutes on day 1</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <description>doxorubicin IV over 5-10 minutes</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fosbretabulin disodium</intervention_name>
    <description>Combined Modality Phase:Patients also receive CA4P IV over 10 minutes weekly on the fifth day of radiotherapy. Beginning 4-6 weeks after the completion of the combined modality phase, patients receive CA4P IV over 10 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 2 courses.</description>
    <other_name>Combretastatin A-4 Phosphate</other_name>
    <other_name>CA4P</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>Beginning on day 22, patients undergo radiotherapy twice daily, 5 days a week, for 3-4 weeks.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed anaplastic or poorly differentiated variant thyroid carcinoma&#xD;
             of either of the following:&#xD;
&#xD;
               -  Regionally advanced disease&#xD;
&#xD;
                    -  Confined to the neck and/or superior mediastinum (i.e., above the level of&#xD;
                       the carina)&#xD;
&#xD;
                    -  Measurable or evaluable* disease&#xD;
&#xD;
               -  Completely resected disease without measurable or evaluable disease NOTE: *At a&#xD;
                  minimum, abnormalities on physical exam or radiographic studies that may not be&#xD;
                  precisely measured but readily followed&#xD;
&#xD;
          -  Must have original/diagnostic tumor blocks available to confirm histopathology and for&#xD;
             tumor microvessel density immunohistochemistry&#xD;
&#xD;
               -  Patients with no available original/diagnostic tumor blocks must have tumor&#xD;
                  accessible for pretreatment needle core biopsy&#xD;
&#xD;
          -  Must undergo indirect and direct laryngoscopy to ensure patency of the trachea/airway&#xD;
             if deemed inoperable, with bulky thyroid/neck masses and/or suspicion of airway&#xD;
             obstruction&#xD;
&#xD;
          -  No distant metastases, including but not limited to, brain metastases, disease below&#xD;
             the level of the carina, pulmonary parenchyma, and hepatic or bony metastases&#xD;
&#xD;
               -  Superior mediastinal disease (i.e., above the level of the carina) in addition to&#xD;
                  regional neck disease is allowed provided the disease can be contained in a&#xD;
                  single radiotherapy port&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute granulocyte count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 75,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 8.5 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
          -  ALT and AST ≤ 3.5 times upper limit of normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  LVEF ≥ 50% by echocardiogram&#xD;
&#xD;
          -  EKG normal&#xD;
&#xD;
          -  No prior angina&#xD;
&#xD;
          -  No prior myocardial infarction (e.g., significant Q waves), QTc &gt; 450 msec, or other&#xD;
             clinically significant abnormalities on ECG&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No uncontrolled atrial arrhythmias or clinically significant arrhythmias, including&#xD;
             any of the following:&#xD;
&#xD;
               -  Conduction abnormality&#xD;
&#xD;
               -  Nodal junctional arrhythmias and dysrhythmias&#xD;
&#xD;
               -  Sinus bradycardia or tachycardia&#xD;
&#xD;
               -  Supraventricular arrhythmias&#xD;
&#xD;
               -  Atrial fibrillation or flutter&#xD;
&#xD;
               -  Syncope or vasovagal episodes&#xD;
&#xD;
          -  No significant heart wall abnormality or heart muscle damage by echocardiogram&#xD;
&#xD;
          -  No uncontrolled hypertension (i.e., blood pressure consistently greater than 150/100&#xD;
             mm Hg irrespective of medication)&#xD;
&#xD;
               -  Hypertension is allowed provided there is clinical documentation of controlled&#xD;
                  blood pressure for 2 months before study entry&#xD;
&#xD;
          -  No symptomatic peripheral vascular disease or cerebrovascular disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No uncontrolled hypokalemia or hypomagnesemia&#xD;
&#xD;
          -  No concurrent serious infection&#xD;
&#xD;
          -  No other nonmalignant uncontrolled medical illness or one whose control may be&#xD;
             jeopardized by the complications of study therapy&#xD;
&#xD;
          -  No grade 2 or greater pre-existing motor or sensory peripheral neuropathy&#xD;
&#xD;
          -  No psychiatric disorder or other condition that would preclude study compliance&#xD;
&#xD;
          -  No conditions associated with QTc prolongation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent biologic therapy&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent hormonal therapy, except for the following:&#xD;
&#xD;
               -  Gonadotropin-releasing hormone agonists for patients with hormone-refractory&#xD;
                  prostate cancer&#xD;
&#xD;
               -  Hormone replacement therapy&#xD;
&#xD;
               -  Oral contraceptives&#xD;
&#xD;
               -  Megestrol for anorexia/cachexia&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior attempt at resection or cytoreduction (e.g., debulking) surgery irrespective of&#xD;
             surgical margins allowed provided there are no distant metastases&#xD;
&#xD;
          -  At least 1 week but no more than 8 weeks since prior surgery and recovered&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other concurrent cytotoxic therapy&#xD;
&#xD;
          -  No other concurrent antineoplastic therapy&#xD;
&#xD;
          -  No other concurrent investigational therapy&#xD;
&#xD;
          -  No concurrent medications known to prolong the QTc interval unless the medication can&#xD;
             be held for at least 4 days during each treatment course&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Panayiotis Savvides, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ireland Cancer Center at University Hosptials Case Medical Center, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Josephine Ford Cancer Center at Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ireland Cancer Center at University Hosptials Case Medical Center, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillman Cancer Center at University of Pittsburgh Cancer Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>February 10, 2004</study_first_submitted>
  <study_first_submitted_qc>February 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2004</study_first_posted>
  <last_update_submitted>June 9, 2010</last_update_submitted>
  <last_update_submitted_qc>June 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2010</last_update_posted>
  <responsible_party>
    <name_title>Panayiotis Savvides, MD</name_title>
    <organization>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</organization>
  </responsible_party>
  <keyword>anaplastic thyroid cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Carcinoma, Anaplastic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Fosbretabulin</mesh_term>
    <mesh_term>Combretastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

